Medicine
Tryngolza 50 mg/0.8 mL injection
Tryngolza 50 mg/0.8 mL injection is a prescription medicine containing Olezarsen for subcutaneous use, marketed by Ionis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store the TRYNGOLZA autoinjector in the refrigerator between 2°C and 8°C (36°F…
Key facts
- Active ingredient (INN)
- Olezarsen
- Brand
- Tryngolza
- Strength
- 50 mg/0.8 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 0.8 mL
- Marketing authorisation holder
- Ionis Pharmaceuticals
- Manufacturer
- Ionis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store the TRYNGOLZA autoinjector in the refrigerator between 2°C and 8°C (36°F and 46°F) in the original carton. Once taken out of the refrigerator, the TRYNGOLZA autoinjector can be stored at room temperature between 15°C and 30°C (59°F and 86°F) in the original carton for up to 6 weeks. If not used within the 6 weeks stored at room temperature, discard TRYNGOLZA. Protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C10AX Cholesterol and lipid-lowering medicines, subgroup C10A, subgroup C10AX
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 June 2026
- Identifiers
- RxCUI 2701422, 2701428, 2746496 +1DailyMed set ID 0f51aa8e-8475-8cf9-e063-6394a90a6848NDC 71860-102Application NDA218614
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / .8 mL in 1 syringe, glass | 71860-102-01 | Ionis Pharmaceuticals | 24 June 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Olezarsen
Clinical summary
Olezarsen is an APOC-III-directed RNA interaction indicated as an adjunct to diet. It is available as injection for subcutaneous use. MedsAcross supplies Olezarsen for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about OlezarsenFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TRYNGOLZA prescribing information (Ionis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Tryngolza: European public assessment report (EPAR) · European Medicines Agency
Need Tryngolza 50 mg/0.8 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.